Predicting cognitive function in Alzheimer's clinical trials via amyloid β-protein biomarkers.
Br J Clin PharmacolJun 28, 2026 (epub)
Zichao Sui, Aobo Feng, Yiwen Gong et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis examined the relationship between amyloid-β biomarkers and cognitive outcomes in Alzheimer's clinical trials, analyzing data from 57 studies involving 93,417 subjects. Significant correlations were found between β-amyloid plaque uptake and cognitive function measures, specifically CDR-SB and ADAS-COG-11. The study established predictive models for cognitive function based on these biomarkers.
Key findings
- Significant correlations were found between SUVR of β-amyloid plaques and CDR-SB.
- A correlation was also established between centiloid and CDR-SB.
- The analysis included 57 articles representing 93,417 subjects.
- Three predictive models for cognitive function scales were developed based on amyloid imaging.
Why it matters
Understanding the relationship between amyloid-β biomarkers and cognitive function is crucial for developing effective Alzheimer's treatments. This research supports the amyloid hypothesis and provides a framework for future therapeutic strategies.